Current Legal Status: MK-677 in 2026
MK-677 (Ibutamoren) has one of the more straightforward legal positions among popular performance peptides. It is not approved, not banned, and not restricted — it exists in the research chemical space with minimal regulatory attention.
Federal Legal Status
FDA Status
MK-677 has not been approved by the FDA for any indication. Lumos Pharma (formerly OligoGene) conducted clinical trials for pediatric growth hormone deficiency, but no approval application has been filed.
| Status | Detail |
|---|---|
| FDA-approved | No |
| Category 2 (compounding ban) | No |
| Controlled substance | No |
| DEA scheduled | No |
| Legal to purchase | Yes (as research chemical) |
| Legal to possess | Yes |
What this means: MK-677 has not attracted the same FDA scrutiny as BPC-157 (Category 2) or compounded semaglutide (shortage list dispute). It occupies a quieter regulatory space.
Why MK-677 Has Less FDA Attention
Several factors explain why MK-677 has avoided regulatory action:
- Oral administration — MK-677 is taken as a capsule or liquid, not injected. This keeps it out of the compounding pharmacy supply chain that the FDA has been targeting
- Not widely prescribed by clinics — unlike BPC-157 or semaglutide, few clinics have built practices around prescribing MK-677
- No brand-name competition — there is no pharmaceutical company with a patented MK-677 product lobbying for enforcement against competitors
- Smaller market — MK-677’s user base is primarily fitness/bodybuilding communities, a smaller footprint than the massive GLP-1 weight loss market
Research Chemical Availability
MK-677 is widely available from research chemical vendors in multiple forms:
| Form | Availability | Notes |
|---|---|---|
| Capsules | Common | Pre-dosed, most convenient |
| Liquid (oral solution) | Common | Allows dose adjustment |
| Powder (raw) | Available | Requires weighing, least convenient |
Quality Verification
Because MK-677 is not FDA-regulated, quality control falls on the buyer:
- Certificate of Analysis (CoA) — third-party HPLC testing showing >98% purity
- Mass spectrometry — confirms correct molecular identity (molecular weight 528.67 Da)
- Vendor reputation — established vendors with consistent testing track records
- Capsule concerns — pre-made capsules have additional risks (incorrect dosing, fillers, contamination) compared to pure powder or liquid
Pricing
MK-677 is one of the more affordable performance compounds:
| Form | Typical Cost | Duration |
|---|---|---|
| Capsules (25mg x 60) | $40-80 | 2 months |
| Liquid (25mg/mL, 30mL) | $30-60 | 1 month |
| Powder (1g) | $20-40 | ~40 days at 25mg/day |
WADA Prohibition
Current Status
MK-677 is on the WADA Prohibited List under:
- Category: S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics
- Subcategory: Growth Hormone Secretagogues
- Timing: Prohibited at all times (in-competition and out-of-competition)
Detection
MK-677 is detectable through standard anti-doping urine testing:
- Detection method: LC-MS/MS (liquid chromatography-tandem mass spectrometry)
- Detection window: MK-677 and its metabolites can be detected for several weeks after cessation
- Half-life consideration: MK-677 has a 24-hour half-life, but metabolites persist longer
Who This Affects
| Organization | MK-677 Status |
|---|---|
| WADA | Prohibited |
| USADA | Prohibited |
| NCAA | Prohibited |
| IOC | Prohibited |
| Most pro sports | Prohibited |
| Untested powerlifting | Not tested |
| Natural bodybuilding (tested) | Prohibited |
| Recreational fitness | Not applicable |
Comparison to Similar Compounds
| Compound | FDA Status | Category 2 | Controlled | WADA | Availability |
|---|---|---|---|---|---|
| MK-677 | Not approved | No | No | Banned | Widely available |
| CJC-1295 | Not approved | No | No | Banned | Widely available |
| Ipamorelin | Not approved | No | No | Banned | Widely available |
| BPC-157 | Not approved | Yes | No | Banned | Available (not from compounding) |
| Sermorelin | Approved (discontinued) | No | No | Banned | Limited pharmaceutical, available research |
| HGH | Approved | N/A | Restricted (1990 Act) | Banned | Prescription only |
MK-677’s advantage: it remains in the least-restricted category — legal to buy, not compounding-restricted, not controlled. Only the WADA prohibition affects a specific subset of users.
Supplement Industry Overlap
MK-677 sometimes appears in the supplement market — either explicitly labeled or hidden in “natural GH booster” products. This creates additional legal considerations:
- DSHEA compliance — MK-677 is not a dietary ingredient and cannot legally be sold as a dietary supplement under the Dietary Supplement Health and Education Act
- FDA enforcement — the FDA has issued warning letters to companies selling MK-677 as a supplement
- Amazon/retail — MK-677 has been removed from major retail platforms; availability is primarily through dedicated research chemical vendors
If you see MK-677 sold as a “supplement” on Amazon or in a retail store, be skeptical. It is either mislabeled, contains no actual MK-677, or the seller is violating FDA regulations.
Looking Ahead
Likely Stable (2026-2027)
- MK-677’s regulatory status is unlikely to change significantly in the near term
- No pharmaceutical company is pursuing FDA approval
- The FDA’s enforcement focus remains on compounding pharmacies and GLP-1 drugs
- Research chemical availability should remain consistent
Possible Risks
- Category 2 expansion — if the FDA broadens its compounding restrictions, MK-677 could be affected (lower probability since it’s not widely compounded)
- SARM/peptide-specific legislation — periodic congressional attention to SARMs could sweep MK-677 into broader legislation, though MK-677 is technically not a SARM
- State-level action — individual states could restrict sale, though none have targeted MK-677 specifically
Related Resources
- MK-677 Protocol — dosing, timing, and cycle guide
- Growth Hormone Peptides Compared — MK-677 vs CJC-1295 vs Ipamorelin
- Peptide Legality & FDA Status Guide — complete overview
- CJC-1295 Legal Status — CJC-1295 regulatory guide
- Peptide Safety Guide — quality, storage, and side effects
Frequently Asked Questions
Is MK-677 legal in the United States? +
Yes. MK-677 (Ibutamoren) is legal to purchase and possess in the United States. It is not FDA-approved, not a controlled substance, and not scheduled by the DEA. It is sold as a research chemical labeled 'not for human consumption.' Unlike some peptides, MK-677 has not been placed on the FDA's Category 2 list, so it has not faced compounding pharmacy restrictions.
Is MK-677 a steroid? +
No. MK-677 is a growth hormone secretagogue — it stimulates the pituitary gland to release growth hormone by mimicking the hormone ghrelin. It is not an anabolic steroid and does not directly affect testosterone or other androgenic hormones. It is taken orally (not injected), which further distinguishes it from injectable peptides and steroids.
Is MK-677 banned by WADA? +
Yes. MK-677 (Ibutamoren) is on the WADA Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth hormone secretagogue. It is prohibited at all times — in-competition and out-of-competition. Any athlete subject to WADA, USADA, or NCAA testing cannot use MK-677.
Can my doctor prescribe MK-677? +
MK-677 is not FDA-approved, so there is no standard prescription pathway. Some anti-aging or wellness clinics have prescribed MK-677 through compounding pharmacies (off-label), but this is not common. The primary access route is through research chemical vendors.
Is MK-677 legal in other countries? +
Legal status varies by country. MK-677 is generally available as a research chemical in most Western countries. In Australia, MK-677 is a Schedule 4 (prescription-only) substance. In the UK, it falls under general supplement regulations but is not specifically scheduled. In China, it is manufactured and exported without restriction. Check your country's specific regulations.
Could MK-677 become a controlled substance? +
Possible but unlikely in the near term. The DEA has not shown interest in scheduling MK-677 specifically. The greater risk is FDA regulatory action similar to what happened to BPC-157 (Category 2 compounding restriction). However, since MK-677 is not widely compounded and is primarily sold as a research chemical, the FDA has less regulatory leverage compared to compounds in the compounding pharmacy supply chain.